Introduction
Approximately 90% of pancreatic cancer (PaC) cases originate from the exocrine duct system as adenocarcinomas. Currently, the median survival rate for patients with pancreatic adenocarcinoma is less than six months and the 5-year survival rate is 5% (1). It is estimated that 33,730 new cases of PaC will be diagnosed in the United States in 2006 and more than 32,000 individuals will die from the disease, making it the fourth most common cause of cancer-related mortality among men and women (1). Diagnosis of PaC is often delayed, mostly because specific symptoms do not occur until later stages of the disease. Detection is further complicated by a lack of diagnostic tests that are sufficiently sensitive and specific to identify PaC in early stages. Current scientific literature suggests that microarray technology is a promising approach for the early detection and treatment of PaC. Indeed, numerous microarray-based studies have identified candidate genes that may some day be used as diagnostic and therapeutic markers. Pancreatic resection is currently the only curative therapy for PaC, which demonstrates a significant level of resistance to chemotherapy (2, 3). However, metastatic disease is present in approximately 80% of patients at the time of diagnosis, making most people ineligible for resection ( Figure 1) .
Microarray Platforms and Sample Collection
Arguably, the most commonly used microarray platforms for gene transcript analysis include the Affymetrix GeneChip® (Santa Clara, CA) and Illumina BeadChip™, (San Diego, CA), although numerous custom and commercial technologies are currently available. Recently, Illumina introduced its Solexa Sequencing Technology, which promises to revolutionize genetic analysis. Originally based on Massively Parallel Signature Sequencing (MPSS™) and Clonal Single Microarray technology, it generates DNA sequence information from millions of DNA fragments in a single experiment and can also be used for gene expression analysis.
Alternate splicing of exons plays an important role in cancer (4). New generations of microarrays, such the genome-wide GeneChip® Exon Array System and GeneChip® Human Tiling arrays recently released by Affymetrix, should facilitate the study of these alterations and may also detect novel gene transcripts that are involved in cancer progression. However, all of the studies identified in this review were conducted with standard expression arrays from either the Affymetrix GeneChip® (Santa Clara, CA) or one of the many commercial or custom spotted array platforms (Table I) .
Methods for tissue collection, preservation, and storage are critical to the success of a microarray experiment (5, 6). Tissues must be preserved under appropriate conditions immediately after collection in order to ensure good quality. Labeled cDNA or cRNA products that originate from degraded or contaminated RNA do not represent accurately the copy number of gene transcripts within a sample. Tissue homogeneity can also affect the outcome of a microarray experiment. Non-cancerous tissue that is resected with tumor tissue may dilute the transcript level of genes that are modified by cancer-specific regulation. For this reason, methods that provide specific tissue or cell types, such as laser capture microdissection (LCM) or fine needle aspiration are now preferable to standard tissue collection methods in order to accumulate tumor-specific cells (7, 8) . Chronic pancreatitis is also known to cause changes in gene transcript levels of the pancreas.
Thus, several studies included controls from both normal and pancreatitis samples in order to provide a subtractive analysis that identifies genes that are specific to PaC.
Data Analysis
The decision to use specific normalization and analysis methods is often based on the overall design and statistical power of an experiment. In part, because of the diverse nature of microarray experimental design, a standardized set of methods, algorithms, or tools for the analysis of microarray data has not been established. Indeed, studies included in this review used a variety of analysis methods. It is well established that the comparison of data by dissimilar methods may yield results that are unique (9). Thus, careful experimental design is essential in order to generate meaningful data. There are many commercial and freeware software applications that are available currently for the analysis of microarray data sets and the subsequent parsing of gene annotations and associated biochemical pathways. Commonly used commercial software for microarray data analysis includes GeneSpring™ (Agilent, Santa Clara, CA), Spotfire Deci-sionsite™ (Somerville, MA), and ArrayAssist Expression™ 
Gene Transcript Analysis in Pancreatic Cancer
In the detection of PaC, microarrays offer unique advantages over other molecular techniques by allowing concurrent interrogation of the complete human genome in a single experiment. The global analysis of gene transcript levels that is afforded by microarrays, and the subsequent identification of aberrant gene regulation, may allow detection of tumor-specific changes in gene expression prior to the onset of physical symptoms.
Numerous studies have identified novel genetic targets for diagnosis and treatment of PaC (10). In this review, we have selected studies that characterize gene transcript alterations and identify candidate gene panels from whole genome arrays and focused arrays (Table I ). In addition, we review the detection of individual candidate genes for early detection and therapeutic intervention of PaC.
Iacobuzio-Donahue and colleagues used the Affymetrix U133 A&B GeneChip® array, which interrogates the whole human genome, to identify a unique set of genes that were upregulated 3-fold or more compared with normal pancreas or duodenal samples (11). Principle Components Analysis (PCA) detected transcripts that are differentially expressed in PaC. Among 217 unique genes that were overexpressed in ductal adenocarcinomas, but not in normal pancreas or pancreatitis, 75 dysregulated genes have also been identified by other groups. Mesothelin, Muc4, Muc5A/C, Kallikrein 10, Transglutaminase 2, Fascin, TMPRSS3, and stratifin were the most highly expressed transcripts in this experiment and were deemed to be suitable candidates for diagnostic and therapeutic markers. However, when the authors performed cross platform comparisons using Affymetrix U133 A&B GeneChips®, spotted cDNA arrays, and SAGE, several discrepancies arose. Only 40 genes were identified by more than one method and only six genes were identified by all three methods (Keratin 19, Retinoic acid induced 3, secretory leukocyte protease inhibitor, stratifin, tetraspan 1, and transglutaminase). Discrepancies such as these emphasize the differences between expression assays and underscore the need for well defined analysis methods that serve to minimize false positives.
Normal parenchyma cells that border pancreatic ductal adenocarcinoma exhibit genetic dysregulation that is an indication of nearby tumorigenesis (12) . In this study, RNA samples from microdissected fresh frozen pancreas tissues were amplified and hybridized onto Affymetrix U133A GeneChips®. Samples from infiltrating pancreatic adenocarcinoma were compared with tissue from normal pancreas and chronic pancreatitis. The authors filtered the dataset, keeping only those genes that were present in at least one of the samples, and then set a fold change cutoff ≥ 3 to identify several expressed candidate genes. Among them, pancreatitis-associated protein (HIP/PAP), lactotransferrin (LTF), human cartilage glycoprotein-39 (HC-gp39), and regenerating islet-derived 1 beta (REG1B) were most highly expressed. A combination of comparative genomic hybridization and gene expression analysis by Affymetrix GeneChip® was used to show a statistical correlation between gene copy number and gene transcript expression (13). Among 603 genes that were differentially expressed in pancreatic adenocarcinoma cell lines and primary tumors, several genes, including MYC, p16, and DUSP6 have previously been associated with PaC.
Both commercial and custom spotted arrays that interrogate the human genome have been used to identify sets of genes that are potential diagnostic markers for PaC. Clontech At-las™ arrays (Mountain View, CA) identified a panel of candidate genes for the discrimination of pancreatic adenocarcinoma from normal pancreas (8). Pancreatic tissue was collected by fine needle aspiration, which allowed the selection of tumor-specific regions. This study confirmed previous reports that caspase 8, TIMP1, CD9, and Il-13 were differentially expressed in PaC and identified several putative markers, including Rac 1, GLG1, NEDD5, RPL-13a, RPS9, and Wnt5A. A follow-up study by this group also used Atlas arrays but incorporated LCM to selectively capture pancreatic ductal cells. In addition to the aforementioned genes, ABL2, Notch4, and SOD1 were also overexpressed in cancer tissues (14).
A custom spotted cDNA array containing more than 23,000 transcripts identified over 600 genes that are dysregulated in pancreatic ductal adenocarcinoma compared to normal pancreatic ductal cells (15). The large number of candidate genes identified in this study was attributed to the use of LCM, which captured a population of PaC cells that was 95% pure. Among the genes identified, 76 were associated with metastasis to lymph nodes and 168 were associated with liver metastasis.
Other studies used arrays that were designed to interrogate specific subsets of the human genome in order to identify genes that are associated with pancreatic adenocarcinoma. Freiss and colleagues used the Affymetrix HuGeneFL array to compare samples from PaC patients with samples from patients with normal pancreas and chronic pancreatitis (16). Among 5600 full length genes present on the HuGeneFL ar- ray, 216 were differentially expressed in PaC with respect to normal pancreas and chronic pancreatitis. An increase in expression was seen in 120 of these genes, whereas 96 showed a decrease in gene transcript levels. In order to confirm the microarray results, northern blot analysis was conducted on five of the dysregulated genes. In each case, the expression level was confirmed. Logsdon and colleagues also used the Affymetrix HuGeneFL array to interrogate transcript copy number in PaC cell lines, chronic pancreatitis, and normal pancreas tissue (17). PCA of 921 highly expressed genes showed a distinct relationship between the sample types, with PaC cell lines more closely related to pancreatic adenocarcinoma than chronic pancreatitis or normal tissue. Significant upregulation in pancreatic adenocarcinoma was identified in 158 transcripts and four candidate genes (14-3-3σ, S100P, S100A6, and β4 Integrin) were identified that are uniquely expressed in pancreatic adenocarcinoma.
Individual genes that exhibit differential expression during PaC can also be used to assess cancer progression (18). Affymetrix U95av2 arrays were used to determine that BNIP3 is downregulated late in the progression of PaC and also facilitates resistance to chemotherapeutic agents 5-fluoro-uracil and gemcitabine (18). However, HoxB2, a component of the retinoic signaling pathway, demonstrated the opposite affect. Upregulation of this gene in pancreatic intraepithelial neoplasia was associated with poor prognosis and was a negative indicator of patient survival following resection (19) . Confirming the findings of Logsdon et al., Ohuchida and colleagues found that S100A6 was also upregulated in PaC and suggested that this gene is a potential diagnostic marker for the disease (17, 20) .
Microarrays have also been used to identify pathways involved in drug resistance and to characterize novel therapeutic treatments and adjuvant therapies (21). The antiapoptosis gene P8 was overexpressed in several PaC cell lines. However, when the authors decreased P8 expression in gemcitabine-resistant cells, apoptosis was increased. Conversely, upregulated P8 expression increased resistance to apoptosis, suggesting that negatively altering the P8 pathway could enhance the ability of gemcitabine to treat PaC.
Conclusion
Advancements in molecular technologies have enhanced the ability of researchers to explore PaC and its progression. However, several factors contribute to poor correlation between studies that use different microarray platforms (Table  I ) (22). Cross-study comparisons of individual gene candidates and expression ratios of genes implicated in PaC are sometimes obfuscated by variations in experimental design, target sequence, analysis methods, and differences in gene annotation. Nonbiological variability that is introduced into an experiment by collection and analysis techniques enhances the potential for false positive and false negative results. Therefore, most studies use other methods for gene transcript analysis, such as quantitative real time RT PCR, serial analysis of gene expression (SAGE), or northern blot, to confirm the results of microarray experiments.
Although some research studies have shown poor correlation of RNA transcript expression, many studies have identified putative markers for the detection and/or treatment of PaC (18, 21, 23, 24) . Indeed, well-defined meta-analysis of studies that use different microarray platforms has confirmed that some transcripts are commonly regulated across multiple studies (23). Well-designed microarray experiments that employ stringent controls and confirmatory tests can identify candidate genes with reasonable certainty, despite the obstacles that are inherent in the interrogation of gene transcripts and their associated splice variants. Collective changes in gene transcript regulation may indeed provide markers for the molecular detection of PaC in the early stages of the disease. However, much remains to be learned about this disease before significant improvements in diagnoses and survival can be realized.
